MDMA Therapy 2026 Update: Where Things Stand After the FDA Rejection
The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024, and as of mid-2026 that decision stands. MDMA remains a Schedule I...
Psychedelic Policy USA 2026: Mid-Year Federal and State Update
Psychedelic policy in the USA is moving faster in 2026 than at any point in recent history. A federal executive order, a wave of state-level bills,...
Psychedelic Therapy in Washington State: Legal Status and Access
Psychedelic therapy in Washington state is an evolving picture. Ketamine is fully legal and widely available across Seattle and the broader Puget Sound area. Psilocybin remains...
Ketamine vs. Esketamine (Spravato): What the Difference Actually Means
Ketamine vs. esketamine (Spravato) is one of the most common points of confusion for people exploring treatment-resistant depression options. Both work through a similar mechanism in...
How to Talk to Your Doctor About Psychedelic Therapy
Talking to your doctor about psychedelic therapy is one of the most common points where people get stuck. This guide walks you through how to frame...
Psychedelic Therapy Washington DC, Maryland & Virginia: 2026 Guide
Last Updated: May 2026 If you’re looking for psychedelic therapy in Washington DC, Maryland, or Virginia (DMV), your clearest option right now is ketamine, which is...
Psilocybin PTSD Therapy: What the 2026 Clinical Evidence Shows
Psilocybin PTSD therapy is no longer a fringe concept. A growing body of clinical research, including Phase 2 trials published in 2025, shows that a single...
MDMA Therapy FDA Decision, What the Rejection Letter Means for Seekers
The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD, citing three specific concerns: gaps in safety reporting, insufficient evidence that benefits lasted over time,...
Ready to take the next step?
Start with a complimentary conversation, or take the two-minute self-evaluation to see if this is your moment.